114 related articles for article (PubMed ID: 26657199)
1. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
Ravandi F; Pigneux A; DeAngelo DJ; Raffoux E; Delaunay J; Thomas X; Kadia T; Kantarjian H; Scheuenpflug J; Zhao C; Guo W; Smith BD
Blood Cancer J; 2015 Dec; 5(12):e375. PubMed ID: 26657199
[No Abstract] [Full Text] [Related]
2. Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
Srinivas NR
Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):373-382. PubMed ID: 29488172
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
Berger R; Rotem-Yehudar R; Slama G; Landes S; Kneller A; Leiba M; Koren-Michowitz M; Shimoni A; Nagler A
Clin Cancer Res; 2008 May; 14(10):3044-51. PubMed ID: 18483370
[TBL] [Abstract][Full Text] [Related]
5. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
von Richter O; Massimini G; Scheible H; Udvaros I; Johne A
Br J Clin Pharmacol; 2016 Dec; 82(6):1498-1508. PubMed ID: 27483391
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
Scheible H; Kraetzer F; Marx A; Johne A; Wimmer E
Drug Metab Dispos; 2017 Feb; 45(2):174-182. PubMed ID: 27934635
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
9. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
Minden MD; Hogge DE; Weir SJ; Kasper J; Webster DA; Patton L; Jitkova Y; Hurren R; Gronda M; Goard CA; Rajewski LG; Haslam JL; Heppert KE; Schorno K; Chang H; Brandwein JM; Gupta V; Schuh AC; Trudel S; Yee KW; Reed GA; Schimmer AD
Am J Hematol; 2014 Apr; 89(4):363-8. PubMed ID: 24273151
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
11. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
14. Treatment decisions for elderly patients with haematological malignancies: a dilemma.
Peyrade F; Gastaud L; Ré D; Pacquelet-Cheli S; Thyss A
Lancet Oncol; 2012 Aug; 13(8):e344-52. PubMed ID: 22846839
[TBL] [Abstract][Full Text] [Related]
15. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
17. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
18. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
[No Abstract] [Full Text] [Related]
19. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Daniele B; Croitoru A; Papandreou C; Bronowicki JP; Mathurin P; Serejo F; Stål P; Turnes J; Ratziu V; Bodoky G
Future Oncol; 2015 Sep; 11(18):2553-62. PubMed ID: 26158398
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
